Alnylam Pharmaceuticals, Inc.(ALNY)

Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Liver Disease Cholesterol Hemophilia Liver Cancer Amyloidosis Huntington's Disease Hypercholesterolemia Deficiency Takeda Pharmaceutical Company Treatment Of Hemophilia Hemoglobin Hemophilia A Spinal Muscular Atrophy Antitrypsin Deficiency Monsanto Alnylam Pharmaceuticals Amyloid Rna Interference Therapeutic Gene Modulation Medtronic Thalassemia Transthyretin Genzyme Treatment Of Huntington's Disease Beta Thalassemia Hemoglobinopathies Acute Intermittent Porphyria Arrowhead Pharmaceuticals

---

Home Page: www.alnylam.com

ALNY Technical Analysis

675 West Kendall Street
Cambridge, MA 02142
United States
Phone: 617 551 8200

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)